Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTILs: Biomarker-Guided De-escalation in Early-Stage TNBC
NCT07743190Phase 2Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Jan 2027
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, Paclitaxel Micelles for Injection and pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Medical University of South Carolina. Primary endpoint: Pathologic Complete Response at 60 months. Planned start Jan 2027; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07743190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743190.